

Annex I

Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="text" value="Nothing new to declare"/>	<input type="text" value="2013"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="text" value="Nothing new to declare"/>	<input type="text" value="2013"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="text"/>	<input type="text"/>
A, part 2 (iii)	<input type="checkbox"/>	<input type="text"/>	<input type="text"/>
B	<input type="checkbox"/>	<input type="text"/>	<input type="text"/>
C	<input type="checkbox"/>	<input type="text"/>	<input type="text"/>
E	<input type="checkbox"/>	<input type="text"/>	<input type="text"/>
F	<input type="checkbox"/>	<input type="text"/>	<input type="text"/>
G	<input type="checkbox"/>	<input type="text" value="Nothing new to declare"/>	<input type="text" value="2013"/>

Date: 9 April 2014

State Party to the Convention: [Australia](#)

Date of ratification/accession to the Convention: [Signed 10 April 1972 and ratified 5 October 1977](#)

National point of contact: [International Security Division, Department of Foreign Affairs and Trade](#)

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:

"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and
- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention, including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

3. Location and postal address

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

⁵ In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Background Information

Australia has four maximum containment units which meet the criteria for a “maximum containment laboratory” as specified in the latest edition of the WHO Laboratory Biosafety Manual.

They are:

- The Australian Animal Health Laboratory (**Attachment 1.2**)
- The National High Security Quarantine Laboratory (**Attachment 1.3**)
- The Queensland Health Forensic and Scientific Services Virology Laboratory (**Attachment 1.4**)
- The Emerging Infectious Diseases and Biohazard Response Unit (**Attachment 1.5**)

Data on these facilities relating to questions 1 to 7 of Form A, Part 1 is attached.

1. Name of facility

Australian Animal Health Laboratory (AAHL)

2. Responsible public or private organisation/company

The Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Federal Government) and the Australian Government Department of Agriculture (Federal Government). AAHL is managed by the CSIRO. Note: Australia has a two-tiered system of Government, with the Federal Government, in collaboration with the six State and two Territory Governments, responsible for the formulation and implementation of national government policy.

3. Location and postal address

Location	Postal address
5 Port Arlington Road East Geelong, Victoria 3219 AUSTRALIA	PMB Bag 24 Geelong Victoria 3220 AUSTRALIA

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Department of Defence. AAHL is funded by the Australian Government, via CSIRO and the Department of Agriculture. It is also funded by other government agencies, industry organisations and commercial companies for specific research and development programs and projects.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

There are four maximum containment (BSL/PC4) facilities. A laboratory of 90 m², two animal facilities of 127m² combined and a combined laboratory/animal facility/insectary of 350m².

6. If no maximum containment unit, indicate highest level of protection

N/A

7. Scope and general description of activities, including type(s) of microorganisms and/or toxins as appropriate.

AAHL plays a vital role in maintaining and improving Australia's capability for timely diagnosis of new and emerging (terrestrial and aquatic) animal diseases, including exotic (foreign) and zoonotic diseases. This is achieved through a dedicated team providing routine and emergency diagnostic services and ongoing research programs to develop or improve diagnostic tests, which are critical to the success of any eradication and/or control campaign in the event of a disease outbreak.

AAHL also undertakes research on new and emerging diseases to better understand the disease process and drivers for their emergence and to develop new diagnostic tests and intervention methods, including vaccines and treatments, for animal diseases of national importance. AAHL is equipped with maximum biocontainment facility which allows it to securely and safely undertake the above-mentioned diagnostic and research activities for animal diseases of national and international significance.

The laboratory is a World Organisation for Animal Health (OIE) reference laboratory for avian influenza, Newcastle disease, bluetongue, Hendra and Nipah virus infection, Abalone Herpes-like virus infection, ranavirus infection, and

epizootic haematopoietic necrosis virus infection. AAHL is also an OIE Collaborating Centre for New and Emerging Diseases, a World Health Organization (WHO) Collaborating Centre for Severe Acute Respiratory Syndrome (SARS), and a national reference laboratory for rabies and *Brucella spp.*

As a microbiologically secure laboratory, AAHL also does work with several security sensitive biological agents (SSBAs) and as such, is a registered SSBA facility and complies with the security requirements of the Australian National Health Security Act, 2007 (detailed in Form E).

1. Name of facility

National High Security Quarantine Laboratory (NHSQL)

2. Responsible public or private organisation/company:

Department of Health (Federal Government), Victorian Department of Human Services (State Government).

3. Location and postal address:

Location	Postal address
Victorian Infectious Diseases Reference Laboratory 792 Elizabeth Street Melbourne VIC 3000 AUSTRALIA	National High Security Quarantine Laboratory c/o VIDRL Locked Bag 815 Carlton South VIC 3053 AUSTRALIA

4. Source(s) of financing, of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Department of Defence. It receives funding from the Commonwealth and State Departments of Health.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

One high security laboratory, containing two portable isolation units. Total area 90m².

6. If no maximum containment unit, indicate highest level of protection

N/A

7. Scope and general description of activities, including type(s) of micro-organism and/or toxins as appropriate

The diagnosis of possible imported cases of viral haemorrhagic fever or other quarantinable diseases that present a significant danger to the Australian community. Development of laboratory tests and protocols for exotic respiratory viral diseases, including *influenzavirus* A/H5N1 ('bird flu') and SARS. In addition, VIDRL has established and maintained the capability to perform diagnostic testing for the *variola* virus. See also background information.

1. Name of facility

Queensland Health Forensic Scientific Services (QHFSS).

2. Responsible public or private organisation/company:

Queensland Department of Health (State Government).

3. Location and postal address:

Location	Postal address
39 Kessels Road Coopers Plains QLD AUSTRALIA	PO Box 594 Archerfield QLD 4108 AUSTRALIA

4. Source(s) of financing, of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Department of Defence. It receives funding from Queensland Department of Health.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

Two. Total area 150m².

If no maximum containment unit, indicate highest level of protection

N/A.

7. Scope and general description of activities, including type(s) of micro-organism and/or toxins as appropriate

The maximum containment facility at QHFSS, a state government public health virology laboratory, has both a diagnostic and a research function. The maximum containment facilities are used for the development and performance of diagnostic tests on patients with suspected exotic or endemic viral illness. This includes Henipah viruses or exotic haemorrhagic fever viruses. The only PC4 level pathogens that the laboratory has are Hendra virus and SARS coronavirus (AQIS QC4), which are used for diagnostic purposes. The laboratory intends to introduce reagents useful for the diagnosis of a number of exotic viral diseases including Ebola, Marburg, Lassa, Junin, Rift Valley fevers and Hantavirus among others. These reagents will consist of either inactivated diagnostic reagents, cloned viral subunits or live virus.

- 1. Name(s) of facility**

Emerging Infectious Diseases and Biohazard Response Unit (EIDBRU).
- 2. Responsible public or private organization or company**

Institute for Clinical Pathology and Medical Research, Pathology West, NSW Health Pathology.
- 3. Location and postal address**

Centre for Infectious Diseases and Microbiology
Laboratory Services (CIDMLS)
ICPMR
Institute Road.
Westmead NSW 2145
- 4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**

This facility receives no funding from the Australian Department of Defence. It is funded by New South Wales Department of Health.
- 5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)**

One maximum containment PC4 unit—Laboratory work area 85.5m².
- 6. If no maximum containment unit, indicate highest level of protection**

N/A
- 7. Scope and general description of activities, including type(s) of microorganisms and/or toxins as appropriate**

Laboratory investigation of human specimens or substances suspected of containing an exotic agent, emerging infectious disease or bioterrorism agent such as pandemic influenza, anthrax and ricin toxin for the state of New South Wales.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents⁶ on a State Party's territory:

Not applicable. Australia has declared maximum containment facilities in Form A, part 1 (i).

Biosafety level 3 ⁷	yes / no
Biosafety level 2 ⁸ (if applicable)	yes / no

Any additional relevant information as appropriate:

⁶ Microorganisms pathogenic to humans and/or animals

⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

⁸ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

- (1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;
- (2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;
- (3) The organizational structure of the programme and its reporting relationships; and
- (4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;
 - (a) location;
 - (b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;
 - (c) the total number of staff employed, including those contracted full time for more than six months;
 - (d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;
 - (e) a list of the scientific disciplines of the scientific/engineering staff;
 - (f) the source and funding levels in the following three areas: research, development, and test and evaluation; and
 - (g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes. Australia has a science and technology program in defence against biological agents, which occurs in the Defence Science and Technology Organisation (DSTO), Department of Defence, as detailed in the attached (see Form A, Part 2 (ii)).

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

The objective of the program is to provide the Australian Government with an appropriate understanding of the issues pertinent to protection against biological weapons. The program contributes to Defence support to the civil authorities in the management of biological threats to the community. The program also assists in the provision of a defensive capability for the Australian Defence Force (ADF) by enhancing the ability of the ADF to operate in parts of the world where biological weapons might be used. It also enhances Australia's ability to contribute to biological arms control verification. The principal research activities are concerned with the detection, diagnosis and analysis of biological species that have been identified as potential biological warfare agents and development of medical countermeasures to those agents. The program also covers toxins that are considered threats in terms of both the Biological and Chemical Weapons Conventions.

2. State the total funding for each programme and its source.

The program is funded solely by the Australian Department of Defence, with an allocation for the calendar year (1 January – 31 December 2013) of approximately \$2 500 000.

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes. Work is contracted to non-defence facilities.

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

For the calendar year 2013, the following payments were made:

- \$30,000 (approx.) to Metabolomics Australia.

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

Metabolomics Australia Pty Ltd was funded to provide Gas Chromatography Mass Spectrometry and Liquid Chromatography Mass Spectrometry analysis of urine samples as part of a predictive diagnosis program.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).

The organisational structure is as follows. There is a single active research cell operating within the Department of Defence within the hierarchy represented below.



7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

See Form A, Part 2(iii) and the associated attachment (**Attachment 2**) for Australia's response.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

Australia's submission of Form A, Part 2 (iii) is at **Attachment 2**.

1. What is the name of the facility?
2. Where is it located (include both address and geographical location)?

3. Floor area of laboratory areas by containment level:

BL2 _____ (sqM)

BL3 _____ (sqM)

BL4 _____ (sqM)

Total laboratory floor area _____ (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel _____

(ii) Division of personnel:

Military _____

Civilian _____

(iii) Division of personnel by category:

Scientists _____

Engineers _____

Technicians _____

Administrative and support staff _____

(iv) List the scientific disciplines represented in the scientific/engineering staff.

(v) Are contractor staff working in the facility? If so, provide an approximate number.

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(vii) What are the funding levels for the following programme areas:

Research _____

Development _____

Test and evaluation _____

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms⁹ and/or toxins studied, as well as outdoor studies of biological aerosols.

⁹ Including viruses and prions.

National biological defence research and development programme**Facilities**

Australia has one facility that meets the criteria of paragraph 7 in Form A, part 2 (ii).

1. Name

Biological Defence Research, Land Division, DSTO.

2. Location

Location	Postal address
506 Lorimer Street Fishermans Bend Victoria AUSTRALIA	Platforms Sciences Laboratory (PSL) 506 Lorimer Street Fishermans Bend Victoria AUSTRALIA

3. Floor Area	BL2	150 square metres
	BL3	60
	BL4	nil

4. Personnel

- (i) There are 23 full-time equivalent positions for the combined biological defence and arms control programs. Due to the allocation of work, this equates to approximately 29 personnel working in this area in 2013.
- (ii) All personnel are civilian.
- (iii) The personnel comprise of 29 scientists, nil engineers, and the full-time equivalent of one shared administrative/support staff.
- (iv) Scientific disciplines represented are biochemistry, molecular biology, microbiology, immunology, chemistry, pharmacology, mathematics and physics.
- (v) There are 3 contracted staff members working on this program at the facility.
- (vi) Research is currently wholly financed by the Department of Defence.
- (vii) Research is funded at approximately \$2 500 000 per annum.
- (viii) Publication in scientific journals is encouraged, as it is a mechanism for staff to maintain their professional status.
- (ix) Relevant publications are listed in Form C.

5. Description of Biological Defence Work

Various types of work are undertaken, as outlined in the following sections:

(1) Detection of biological entities recognised as potential biological warfare agents

Immunological and gene-based techniques for rapid identification of BWA (Biological Warfare Agents) have been developed.

Poly and monoclonal antibodies are being produced against several BWA, including *Burkholderia pseudomallei*, *Bacillus anthracis*, anthrax toxins and ricin. Some of the antibodies are being evaluated as molecular recognition reagents for the detection of respective target agents.

Current research focuses on the evaluation of DNA-based and immunoassay platforms, and reagents that enable rapid identification and characterisation of bacterial, viral and toxin agents, including microbial antibiotic resistance and genetically manipulated bacteria.

(2) Development of predictive diagnostics and health monitoring systems for BWA

A predictive diagnostics program has been established, that aims to develop point-of-care platforms that allow pre-symptomatic detection and diagnosis of BWA. Current work involves the use of metabolomic and proteomic techniques to identify biofluid markers in the host that appear on exposure to detect early infection in humans.

A recently established virology program that is integrated with the predictive diagnostics program aims to monitor ADF personnel for viruses causing encephalitis symptoms such as Ross River Virus, Murray Valley Encephalitis Virus, bunya - viruses and rabdo – viruses.

(3) Physical methods for rapid detection of bio-aerosols

Methods of particle characterisation for provision of rapid warning of a bio-aerosol are being assessed.

(4) Protection/Treatment/Toxicology

Neutralization and cytotoxicity assays have been developed to assess the usefulness of potential therapeutic agents such as antibodies and antimicrobial peptides. Platforms for the amplification of antibody avidity, such as self-assembling gels, are also being investigated.

Data mining and bioinformatics have been used to identify key virulence factors that are present in multiple bacterial pathogens including the intracellular bacterium *Coxiella burnetii* which causes the disease Q fever in humans. Some of these virulence factors have been evaluated as the targets for drug development. In addition, an *in-house* capability to grow *C. burnetii* in a host-cell free environment has been developed to facilitate further studies into enhanced medical countermeasures against this bacterium.

Human and mouse lung cells have been used as a test bed for examining potential therapeutic compounds against toxin agents. Compounds for treatment of ricin intoxication are currently being examined.

(5) Detection of biological toxins using physico-chemical methods

Studies on detection of biological material using mass spectrometry and other physico-chemical methods are being conducted to determine their utility for field detection of biological toxins and BWC verification procedures. This work has included the analysis of ricin and crude extracts of ricin by MALDI and FT-ICR mass spectrometry.

(6) Strengthening the Biological Weapons Convention (BWC)

A number of BWC/Biosecurity Regional Workshops have been convened and/or supported by Australia since 2005, with scientific and technical support provided by DSTO. The objectives of these workshops has been to assist BWC States Parties in the Asia-Pacific region become more engaged with the Geneva-based intersessional program of work as a means to reduce the possibility of bioterrorism in the region, or the inadvertent assistance by states in the region to biological weapons programs being developed elsewhere. This outreach process has also led to regional countries conducting their own specialised workshops on biosafety and biosecurity, including the Regional BWC Workshop in Manila in July 2011.

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

At the Third Review Conference it was agreed that States Parties continue to implement the following:

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

The Seventh Review Conference agreed the following:

No universal standards exist for what might constitute a deviation from the normal pattern.

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

1. Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:
 - When the cause of the outbreak cannot be readily determined or the causative agent¹⁰ is difficult to diagnose,
 - When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the latest edition of the WHO Laboratory Biosafety Manual,
 - When the causative agent is exotic to a given geographical region,
 - When the disease follows an unusual pattern of development,
 - When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A,
 - When suspicions arise of the possible occurrence of a new disease.
2. In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that seems to deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form B should be used, to the extent information is known and/or applicable, for the exchange of annual information.
3. The declaration of electronic links to national websites or to websites of international, regional or other organizations which provide information on disease

¹⁰ It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering.

outbreaks (notably outbreaks of infectious diseases and similar occurrences caused by toxins that seem to deviate from the normal pattern) may also satisfy the declaration requirement under Form B.

4. In order to improve international cooperation in the field of peaceful bacteriological (biological) activities and in order to prevent or reduce the occurrence of ambiguities, doubts and suspicions, States Parties are encouraged to invite experts from other States Parties to assist in the handling of an outbreak, and to respond favourably to such invitations, respecting applicable national legislation and relevant international instruments.

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern¹¹

In 2013, Australia had no outbreaks of infectious diseases or similar occurrences caused by toxins that seemed to deviate from the normal pattern. However, the following Attachments 3.1, 3.2 and 3.3 provide information on outbreaks of infectious disease and similar occurrences in humans, animals and plants.

1. Time of cognizance of the outbreak

2. Location and approximate area affected

3. Type of disease/intoxication

4. Suspected source of disease/intoxication

5. Possible causative agent(s)

6. Main characteristics of systems

7. Detailed symptoms, when applicable

- respiratory

- circulatory

- neurological/behavioural

- intestinal

- dermatological

- nephrological

- other

8. Deviation(s) from the normal pattern as regards
- type

¹¹ See paragraph 2 of the chapeau to Confidence-Building Measure B.

- development

- place of occurrence

- time of occurrence

- symptoms

- virulence pattern

- drug resistance pattern

- agent(s) difficult to diagnose

- presence of unusual vectors

- other

- 9. Approximate number of primary cases

- 10. Approximate number of total cases

- 11. Number of deaths

- 12. Development of the outbreak

- 13. Measures taken

Human diseases

The Australian Government Department of Health (Health), through the Office of Health Protection, has overall responsibility for national communicable disease surveillance. State and territory health departments collect notifications of communicable diseases from doctors, hospitals and/or laboratories under their public health legislation.

In September 2007, the *National Health Security Act 2007* received Royal Assent. This Act provides a legislative basis for and authorises the exchange of information, including personal information, between states and territories and the Australian Government. The Act provides for the establishment of the National Notifiable Diseases List (NNDL), which specifies the diseases about which personal information can be provided. There are currently 69 diseases on the NNDL which can be found at: <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-distype.htm>. The *National Health Security Agreement*, which was drafted in 2007 and signed by Health Ministers in 2008, establishes operational arrangements to formalise and enhance existing surveillance and reporting systems. Under the Agreement states and territories forward de-identified data on the nationally agreed set of communicable diseases to the Department's National Notifiable Diseases System database (<http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-nndssintro.htm>) for the purposes of national communicable disease surveillance. The diseases HIV, AIDS, CJD and vCJD are reported through different mechanisms.

Further information is collected from other national, state and sentinel surveillance systems to supplement notifications data for some diseases. This includes data on syndromes, severity, strains and risk factors.

The Department of Health is responsible for timely and accurate intelligence-gathering, analysis and reporting of communicable diseases, both current and emerging, and coordinates the provision of fortnightly summary reports through the Communicable Diseases Network Australia (CDNA) (<http://www.health.gov.au/cdnareport>), and quarterly data summaries and annual reports published in *Communicable Diseases Intelligence* (<http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-cdi-cdiintro.htm>). *Communicable Diseases Intelligence* is also published on the Department's website.

CDNA provides national public health co-ordination on communicable disease surveillance, prevention and control, and offers strategic advice to governments and other key bodies on public health actions to minimise the impact of communicable diseases in Australia and the region. Its members include representatives from the Australian commonwealth, state and territory governments, New Zealand, key organisations in the communicable diseases field, and others with relevant expertise. CDNA holds fortnightly teleconferences to share and evaluate the latest information and developments in communicable diseases surveillance and enables federal and state health authorities to cooperate in taking prompt action to control outbreaks.

No. of cases of Nationally Notifiable Communicable Diseases in Humans, 2009 to 2013

Disease	2009	2010	2011	2012	2013
Bloodborne diseases					
Hepatitis (NEC)	-	-	-	-	-
Hepatitis B (newly acquired)	250	228	194	198	168
Hepatitis B (unspecified)	7,128	6,961	6,562	6,518	7,032
Hepatitis C (newly acquired)	399	400	412	468	390
Hepatitis C (unspecified)	11,109	11,098	9,887	9,650	10,348
Hepatitis D	35	36	39	31	53
Gastrointestinal diseases					
Botulism	1	-	2	-	4
Campylobacteriosis	16,104	16,989	17,725	15,654	14,676
Cryptosporidiosis	4,624	1,481	1,810	3,142	3,851
Haemolytic uraemic syndrome (HUS)	13	9	13	20	14
Hepatitis A	563	267	145	166	189
Hepatitis E	33	37	41	35	32
Listeriosis	92	71	70	93	76
Shiga Toxin-producing <i>E. Coli</i> or Verotoxin-producing <i>E. Coli</i> (STEC/VTEC)	128	80	95	111	179
Salmonellosis	9,504	11,912	12,275	11,259	12,844
Shigellosis	616	552	493	548	554
Typhoid Fever	115	96	135	125	149
Quarantinable diseases					
Cholera	5	3	6	5	3
Highly pathogenic avian influenza (human)	-	-	-	-	-
Plague	-	-	-	-	-
Rabies	-	-	-	-	-
Severe Acute Respiratory Syndrome (SARS)	-	-	-	-	-
Viral haemorrhagic fever (NEC)	-	-	-	-	-
Yellow fever	-	-	2	-	-
Sexually transmissible infections					
Chlamydial infection	63,011	74,326	80,917	82,948	82,385
Donovanosis	1	1	-	1	-
Gonococcal infection	8,279	10,323	12,100	13,850	14,951
Syphilis - congenital	3	3	7	1	7
Syphilis – less than 2 years duration	1,314	1,117	1,323	1,557	1,747
Syphilis – greater than 2 years or unspecified duration	1,442	1,324	1,309	1,377	1,710
Vaccine preventable diseases					
Diphtheria	-	-	4	-	2
<i>Haemophilus influenzae</i> type b	19	24	13	15	20

Disease	2009	2010	2011	2012	2013
Influenza (laboratory confirmed)	59,029	13,468	27,224	44,578	28,296
Measles	104	70	194	199	158
Mumps	166	98	155	200	218
Pertussis	30,158	34,817	38,725	24,082	12,326
Pneumococcal disease - invasive	1,558	1,642	1,884	1,824	1,544
Rubella	27	44	58	37	26
Rubella - congenital	-	-	-	1	2
Tetanus	3	2	3	7	4
<i>Varicella zoster</i> infection – Chickenpox	1,796	1,792	2,100	1,979	2,030
<i>Varicella zoster</i> infection - Shingles	2,778	3,046	4,024	4,510	4,992
<i>Varicella zoster</i> infection - Unspecified	6,762	7,269	7,690	8,437	9,954
Vectorborne diseases					
Arbovirus infection (NEC)	6	14	18	9	21
Barmah Forest virus infection	1,473	1,470	1,863	1,724	4,244
Chikungunya virus infection	30	62	39	19	131
Dengue virus infection	1,402	1,227	821	1,535	1,839
Japanese encephalitis virus infection	-	-	-	1	4
Kunjin virus infection	2	2	2	-	3
Malaria	505	405	418	345	414
Murray Valley encephalitis virus infection	4	-	16	1	1
Ross River virus infection	4,742	5,129	5,136	4,686	4,296
Zoonoses					
Anthrax	-	1	-	-	-
Australian bat lyssavirus	-	-	-	-	1
Brucellosis	32	21	38	30	15
Leptospirosis	141	132	215	116	97
Lyssavirus (NEC)	-	-	-	-	-
Ornithosis (otherwise known as Psittacosis)	65	61	91	75	48
Q fever	313	335	351	363	470
Tularaemia	-	-	2	-	-
Other bacterial infections					
Legionellosis	301	304	360	381	500
Leprosy	5	10	10	7	13
Meningococcal disease -invasive	260	228	242	223	149
Tuberculosis	1,306	1,368	1,385	1,324	1,266

NEC - Not Elsewhere Classified

Animal disease

The Australian Government Department of Agriculture is responsible for national coordination on animal health matters and for providing reports on Australia's animal health status, including a joint annual return to the World Organisation for Animal Health (OIE), the Food and Agriculture Organization (FAO) and the WHO.

The following sections contain information on significant animal disease events/issues in 2013. Australia publishes quarterly reports¹² and annual reports¹³ on animal health incidents and status, as well as providing emergency, six-monthly and annual reports to the OIE¹⁴. Australia's status for OIE-listed diseases for 2013 is shown in the table that follows. Diseases specific to aquatic animals can be found on the Australian Government Department of Agriculture's website (<http://daff.gov.au/animal-plant-health/aquatic/reporting/reportable-diseases>).

Australia's status for OIE-listed diseases of terrestrial animals, 2013

Disease	Status	Date of last occurrence and notes
Multiple-species diseases		
Anthrax	Present	Limited distribution
Aujeszky's disease	Free	Never occurred
Bluetongue	Viruses present	Restricted to specific northern areas of Australia; sentinel herd program
Brucellosis (<i>Brucella abortus</i>)	Free	Australia declared freedom in 1989
Brucellosis (<i>B. melitensis</i>)	Free	
Brucellosis (<i>B. suis</i>)	Serological evidence	Maintained in feral pigs in northern Australia; rare occurrence in domestic pigs*
Crimean Congo haemorrhagic fever	Free	Never occurred
Echinococcosis/hydatidosis	Present	
Epizootic haemorrhagic disease	Virus present	Disease has not been reported
Equine encephalomyelitis (eastern)	Free	Never occurred
Foot-and-mouth disease	Free	1872; officially recognised by the OIE as free without vaccination
Heartwater	Free	Never occurred
Japanese encephalitis	Serological evidence	Detected annually in Torres Strait, and on Cape York in 1998 and 2004
New World screw-worm fly (<i>Cochliomyia hominivorax</i>)	Free	Never occurred
Old World screw-worm fly (<i>Chrysomya bezziana</i>)	Free	Never occurred
Paratuberculosis	Present	National control/management programs
Q fever	Present	
Rabies	Free	1867
Rift Valley fever	Free	Never occurred
Rinderpest	Free	1923; with the global eradication of rinderpest finalized in 2011, all countries are free
Surra (<i>Trypanosoma evansi</i>)	Free	Never occurred

¹² <http://www.animalhealthaustralia.com.au/status/ahsq.cfm>

¹³ <http://www.animalhealthaustralia.com.au/status/ahia.cfm>

¹⁴ <http://web.oie.int/wahis/public.php?page=home>

Trichinellosis	Not reported	Trichinella spiralis not present; T. pseudospiralis present in wildlife
Tularaemia	Free	Never occurred
Vesicular stomatitis	Free	Never occurred
West Nile fever	Australian variants present	A previously unknown Australian strain of West Nile virus was identified following an outbreak of neurological disease in horses in 2011. No cases were reported in 2012 or 2013.
Cattle diseases		
Bovine anaplasmosis	Present	
Bovine babesiosis	Present	
Bovine genital campylobacteriosis	Present	
Bovine spongiform encephalopathy	Free	Never occurred; National Transmissible Spongiform Encephalopathy Freedom Assurance Program includes surveillance; official OIE 'negligible risk' status
Bovine tuberculosis	Free	Australia declared freedom in 1997; last case in any species (including free-living) reported in 2002
Bovine viral diarrhoea	Present	Bovine viral diarrhoea virus (BVDV)-1 — present; BVDV-2 - never occurred
Contagious bovine pleuropneumonia	Free	1967; Australia declared freedom in 1973; officially recognised by the OIE as free
Enzootic bovine leucosis	Very low prevalence in beef cattle	The Australian dairy herd achieved freedom status from the disease on 31 December 2012.
Haemorrhagic septicaemia	Free	Never occurred; strains of Pasteurella multocida present, but not the 6b or 6e strains that cause haemorrhagic septicaemia
Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis	Present	Bovine herpesvirus (BHV)-1.2b — present; BHV-1.1 and 1.2a — never occurred
Lumpy skin disease	Free	Never occurred
Theileriosis	Free	Theileria parva and T. annulata not present
Trichomonosis	Present	
Trypanosomosis (tsetse borne)	Free	Never occurred
Sheep and goat diseases		
Caprine arthritis–encephalitis	Present	Voluntary accreditation schemes exist
Contagious agalactia	Not reported	Mycoplasma agalactiae has been isolated, but Australian strains do not produce agalactia in sheep
Contagious caprine pleuropneumonia	Free	Never occurred
Enzootic abortion of ewes (ovine chlamydiosis)	Not reported	Never occurred
Maedi–visna	Free	Never occurred
Nairobi sheep disease	Free	Never occurred
Ovine epididymitis (Brucella ovis)	Present	Voluntary accreditation schemes in all states
Peste des petits ruminants	Free	Never occurred
Salmonellosis (Salmonella Abortusovis)	Free	Never occurred; surveillance has shown no evidence of infection in sheep
Scrapie	Free	1952
Sheep pox and goat pox	Free	Never occurred
Equine diseases		
African horse sickness	Free	Never occurred
Contagious equine metritis	Free	1980
Dourine	Free	Never occurred
Equine encephalomyelitis (western)	Free	Never occurred
Equine infectious anaemia	Present	Limited distribution/sporadic occurrence
Equine influenza	Free	Australia's first outbreak of equine influenza occurred between 24 August and 25 December 2007; Australia declared freedom

Equine piroplasmosis	Free	according to OIE standards on 25 December 2008
Equine rhinopneumonitis	Present	1976
Equine viral arteritis	Serological evidence	
Glanders	Free	1891
Venezuelan equine encephalomyelitis	Free	Never occurred
Swine diseases		
African swine fever	Free	Never occurred
Classical swine fever	Free	1962
Nipah virus encephalitis	Free	Never occurred
Porcine cysticercosis	Free	Never occurred
Porcine reproductive and respiratory syndrome	Free	Never occurred
Swine vesicular disease	Free	Never occurred
Transmissible gastroenteritis	Free	Never occurred
Avian diseases		
Avian chlamydiosis	Present	
Avian infectious bronchitis	Present	
Avian infectious laryngotracheitis	Present	
Avian mycoplasmosis (<i>Mycoplasma gallisepticum</i>)	Present	
Avian mycoplasmosis (<i>M. synoviae</i>)	Present	
Duck virus hepatitis	Free	Never occurred
Fowl typhoid	Free	1952
Highly pathogenic avian influenza	Free as of 20 March 2013	An outbreak was reported to the OIE on 15 November 2012. Destruction, decontamination and disinfection were completed on the 20 December 2012.
Infectious bursal disease (Gumboro disease)	Present	Infectious bursal disease occurs in a mild form; very virulent strains not present
Low pathogenic notifiable avian influenza (poultry)	Occasional reports	An outbreak was reported to the OIE on 8 March 2013. The outbreak was resolved on 27 June 2013.
Newcastle disease in poultry	Lentogenic viruses present	Virulent Newcastle disease last occurred in poultry 2002**
Pullorum disease	Not reported	Last reported in 1992. <i>Salmonella pullorum</i> has been eradicated from commercial chicken flocks.
Turkey rhinotracheitis	Free	Never occurred
Lagomorph diseases		
Myxomatosis	Present	Used as a biological control agent for wild rabbits
Rabbit haemorrhagic disease	Present	Used as a biological control agent for wild rabbits
Bee diseases		
Acarapisosis of honey bees	Free	Never occurred
American foulbrood of honey bees	Present	
European foulbrood of honey bees	Present	
Small hive beetle	Present	Restricted distribution
Tropilaelaps of honey bees	Free	Never occurred
Varroosis of honey bees	Free	Varroa destructor has never been reported in Australia
Other diseases		
Camel pox	Free	Never occurred
Leishmaniosis	Australian variant present	Rarely, an Australian <i>Leishmania</i> variant has been isolated from skin lesions of macropods. In 2012 a case of leishmaniosis was reported in an imported dog.

OIE = World Organisation for Animal Health

* *B. suis* has also, rarely, been isolated in dogs.

** In August 2011 a paramyxovirus not previously reported in Australia was detected in hobby pigeons in Victoria. Disease cause by this avian paramyxovirus has not spread to poultry.

Australia's status for other diseases of terrestrial animals that are reported to the OIE each year, 2013

Disease	Status	Date of last occurrence and notes
Actinomycosis	Present	
Avian encephalomyelitis	Present	
Avian leucosis	Present	
Avian salmonellosis (excluding fowl typhoid and pullorum disease)	Present	
Avian spirochaetosis	Present	
Blackleg	Present	
Botulism	Present	
Caseous lymphadenitis	Present	
Coccidiosis	Present	
Contagious ophthalmia	Present	
Contagious pustular dermatitis	Present	
Distomatosis (liver fluke)	Present	Restricted distribution
Enterotoxaemia	Present	
Equine coital exanthema	Present	
Filariosis	Present	
Footrot	Present	Restricted distribution
Infectious coryza	Present	
Intestinal <i>Salmonella</i> infections	Present	
Listeriosis	Present	
Melioidosis	Present	Restricted distribution
Nosemosis of bees	Present	
Salmonellosis (<i>Salmonella</i> Abortusequi)	Free	Never reported
Sheep mange	Free	1896
Strangles	Present	
Swine erysipelas	Present	
Toxoplasmosis	Present	
Ulcerative lymphangitis	Free	Never reported
Vibrionic dysentery	Present	
Warble fly infestation	Free	Never reported
Other clostridial infections	Present	
Other pasteurelloses	Present	

Comments on selected OIE-listed diseases

Anthrax

Anthrax is on the list of nationally notifiable diseases and is subject to compulsory government controls, including quarantine, disposal of carcasses, and vaccination and tracing of at-risk animals and their products. Areas at risk of anthrax occurrence are well defined; they include the northern and north-eastern districts of Victoria and central New South Wales. In these areas, anthrax has a low prevalence and occurs only sporadically. Anthrax has never been recorded in the Northern Territory. In Queensland, the last confirmed cases were in 2002 and 1993. South Australia's last recorded anthrax outbreak was in 1914 and Tasmania's was more than 75 years ago. The last case in Western Australia was an isolated case in 1994. In Victoria the last cases of anthrax were in 2009. Anthrax occurred in New South Wales in 2013. Anthrax is considered a tier 1 security sensitive biological agent in Australia and is subject to requirements under the National Health Security Act 2007.

Plant pests and diseases ¹⁵

The Australian Government Department of Agriculture, through the Office of the Chief Plant Protection Officer, is the peak organisation responsible for gathering information on pests of plants. The Department is notified of exotic incursions through State and Territory government agricultural, forestry and natural resource agencies. It provides national leadership in responding to incursions of exotic pests and diseases of plants.

New exotic plant pests and diseases recorded in Australia for 2013

Pest/disease	Scientific Name	Pest/disease Type	Host/Commodity	Notification date
Melon necrotic spot virus	<i>Melon necrotic spot virus</i>	Virus	Watermelon (<i>Citrullus lanatus</i>)	16/01/13
Olive bark Midge	<i>Resseliella oleisuga</i>	Midge	Bonsai olive and feral olive	02/04/13
Erythina gall wasp	<i>Quadrastichus erythrinae</i>	Wasp	Coral tree (<i>Erythrina variegata</i>)	14/05/13
Browsing ant	<i>Lepisiota frauenfeldi</i>	Ant	Vegetation along road (includes Eucalypts, Banksias, Paperbarks, Myrtaceae and lawn alongside footpaths), favouring flowering plants.	17/05/13
Cotton leaf miner	<i>Phyllonorycter triarcha</i>	Moth	Upland cotton or Mexican cotton (<i>Gossypium hirsutum</i>)	29/05/13
Banana Freckle	<i>Phyllosticta cavendishii</i>	Fungi	Banana (Cavendish)	24/07/13

¹⁵ Websites that regularly report plant pests and diseases are: <http://www.planthealthaustralia.com.au/go/phau/strategies-and-policy/national-plant-biosecurity-status-report>, and <http://www.outbreak.gov.au/>.

Sooty mould	<i>Microthyriales</i>	Fungi	Curry tree (<i>Murraya koenigii</i>)	29/07/13
Tomato red spider mite	<i>Tetranychus evansi</i>	Mite	Blackberry nightshade (<i>Solanum nigrum</i>)	22/08/13
American Hop Latent Virus	<i>American Hop Latent Virus</i>	Virus	Hops (<i>Humulus lupulus</i>)	22/08/13
Hackberry woolly aphid	<i>Shivapis celti</i>	Aphid	Chinese hackberry (<i>Celtis sinensis</i>)	02/10/13
Gall mite	<i>Tetra martini</i>	Mite	Kangaroo apple (<i>Solanum aviculare</i>)	08/10/13
Phytophthora alticola	<i>Phytophthora alticola</i>	Fungi	Banksia media; <i>Eucalyptus spp</i> , <i>B. grandis</i> , <i>Xanthorrhoea preissii</i>	01/11/13

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Australia's submission of Confidence Building Measure "C" with respect to the Defence Science and Technology Organisation (DSTO) and the Australian Animal Health Laboratory (AAHL) is as follows:

Land Division, Defence Science Technology Organisation (DSTO)

The policy of the Defence Science and Technology Organisation is to publish results of general scientific value in open literature. Information that is more specialised and relevant particularly to defence is published in laboratory reports, which are unclassified and available to the public, unless they contain information that might prejudice the security of Australia or information that is "commercial-in-confidence". Most results of the biological research will be either unclassified or "commercial-in-confidence".

Over the past 12 months, the following article has been published / accepted for publishing in Australian and international scientific literature:

Lisanby, M., Beer, M., Unsworth, N., and Liu, CQ., "Genome-wide investigation of the host microRNA response to *coxiella burnetii* infection in human macrophage cells." ComBio, Perth, September 2013.

Australian Animal Health Laboratory (AAHL)

Consistent with the goal of encouraging publication of results and promotion of use of knowledge, AAHL has compiled the following list of relevant contributions

Journal articles

1. Bain, Peter; Hutchinson, Rhonda; Marks, Alexandra; Crane, Mark; Schuller, Kathryn. Establishment of a continuous cell line from southern bluefin tuna (*Thunnus maccoyii*). *Aquaculture*. 2013; 376-379:59-63.
2. Baker, Kate; Leggett, Richard; Bexfield, Nicholas; Alston, Mark; Daly, Gordan; Todd, Shawn; et al. Metagenomic study of the viruses of African straw-coloured fruit bats: Detection of a chiropteran poxvirus and isolation of a novel adenovirus.. *Virology*. 2013; 441(2):95-106.
3. Baker, Kate; Suu-Ire, R.; Barr, Jenn; Hayman, David; Broder, Christopher; Horton, D.L.; et al. Viral antibody dynamics in a chiropteran host. *Journal of Applied Ecology*. 2013; 82(6):1-14.
4. Baker, Kate; Todd, Shawn; Marsh, Glenn; Cramer, Gary; Barr, Jenn; Kamins, Alex; et al. Novel, potentially zoonotic paramyxoviruses from the African straw-colored fruit bat *Eidolon helvum*. *Journal of Virology*. 2013; 87(3 1348-1358):1348-1358.
5. Baker, Michelle; Schountz, Tony; Wang, Linfa. Antiviral immune responses of bats: a review. *Zoonoses and Public Health*. 2013; 60:104-116.
6. Blasdel, Kim; Adams, Mat; Davis, Steven; Walsh, Susan; Klement, Eyal; Tesh, Robert; et al. A reverse-transcription PCR method for detecting all known ephemeroviruses in clinical samples. *Journal of Virological Methods*. 2013; 191(2):128-135.
7. Breed, Andrew; Meers, Joanne; Sendow, Indrawati; Bossart, Katharine; Barr, Jenn; Smith, Ina; et al. The Distribution of Henipavirus in Southeast Asia and Australasia: Is Wallace's Line a Barrier to Nipah Virus?. *PLoS ONE*. 2013; 8(4):e6131.
8. Broder, Christopher; Xu, Kai; Nikolov, Dimitar; Zhu, Zhongyu; Dimitrov, Dimiter; Middleton, Deborah; et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. *Antiviral Research*. 2013; 100(1):8-13.
9. Cao, Yu; Colegate, Steven; Edgar, John. Persistence of Echimidine, a Hepatotoxic Pyrrolizidine Alkaloid, from Honey into Mead.. *Journal of Food Composition and Analysis*. 2013; 29:106-109.
10. Cass, Pete; Knower, Warren; Hinton, Tracey; Shi, Shuning; Grusche, Felix; Tizard, Mark; et al. Synthesis and evaluation of degradable polyurea block copolymers as siRNA delivery agents. *Acta Biomaterialia*. 2013; 9(9):8299-8307.
11. Clayton, Bronwyn; Wang, Linfa; Marsh, Glenn. Henipaviruses: an updated review focusing on the pteropid reservoir, and features of transmission. *Zoonoses and Public Health*. 2013; 60(1):69-83.
12. Crane, Mark; Carson, Jeremy; Zainathan, Sandra; Nowak, Barbara. Laboratory evaluation of sample collection methods (organs versus swabs) for Tasmanian salmon reovirus detection in farmed Atlantic salmon, *Salmo salar* L.. *Journal of Fish Diseases*. 2013; 36(5):427-436.
13. Crane, Mark; Corbeil, Serge; Williams, Nette; McColl, Ken; Gannon, Vin. Evaluation of Abalone Viral Ganglioneuritis Resistance Among Wild Abalone Populations Along the Victorian Coast of Australia. *Journal of Shellfish Research*. 2013; 32(1):67-72.

14. Croser, Emma; Marsh, Glenn. The changing face of the Henipaviruses. *Veterinary Microbiology*. 2013; 167:151-158.
15. Cui, Jie; Eden, John-Sebasitan; Holmes, Edward C; Wang, Linfa. Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus. *Virology Journal*. 2013; 10(304):1-5.
16. Curran, John; Robertson, Ian; Ellis, Trevor; Selleck, Paul. Evaluation of avian influenza serological and virological diagnostic methods in wild anseriformes and charadriiformes. *Avian Diseases*. 2013; online in press:6.
17. Curran, John; Robertson, Ian; Selleck, Paul; O'Dea, Mark. Variation in the responses of a wild species of duck, gull and wader to inoculation with a wild bird-origin H6N2 low pathogenicity avian influenza virus. *Avian Diseases*. 2013; 57(3):581-586.
18. Dang, Vinh; Benkendorff, Kirsten; Corbeil, Serge; Williams, Nette; Hoad, John; Crane, Mark; et al. Immunological changes in response to herpesvirus infection in abalone *Haliotis laevigata* and *Haliotis rubra* hybrids.. *Fish & Shellfish Immunology*. 2013; 34(2 0):688-691.
19. Diditchenko, S; Gille, Andreas; Pragst, I; Stadler, D; Imboden, M; Waelchli, M; et al. A novel formulation of a reconstituted HDL (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2013; online in press:15.
20. Eagles, Debbie; Walker, Peter; Zalucki, Myron; Durr, Peter. Modelling spatio-temporal patterns of long-distance *Culicoides* dispersal into northern Australia. *Preventive Veterinary Medicine*. 2013; 110(3-4):312-322.
21. El-Hage, Charles; Savage, Kate; Minke, Jules; Ficorilli, Nino; Watson, James; Gilkerson, James. Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to Equine Influenza.. *Equine Veterinary Journal*. 2013; 45(2):235-239.
22. Epstein, Jonathan; Baker, Michelle; Zambrano-Torrel, Carlos; Middleton, Deborah; Barr, Jenn; DuBovi, Edward; et al. Duration of maternal antibodies against Hendra virus and canine distemper virus in Pteropid bats. *PLoS One*. 2013; 8(6):e67584.
23. Foord, Adam; White, John; Colling, Axel; Heine, Hans. Microsphere suspension array assays for detection and differentiation of Hendra and Nipah viruses. *BioMed Research International*. 2013; 2013:Article ID 289295.
24. Ge, Xingyi; Li, Jia-Lu; Yang, Xing-Lou; Chmura, Aleksei; Zhu, Guangjian; Epstein, Jonathan; et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. *Nature*. 2013; online in press:16.
25. Ghedin, Elodie; Rogers, Matthew; Widen, Steve; Guzman, Hilda; Travassos da Rosa, Amelia; Wood, Thomas; et al. Kolente virus, a novel rhabdovirus isolated from ticks and bats in the Republic of Guinea. *Journal of General Virology*. 2013; 94:2609-2615.
26. Gillespie, Meagan; Crowley, Tamsyn; Haring, Volker; Wilson, Susanne; Harper, Jenni; Payne, Jean; et al. Transcriptome analysis of pigeon milk production - role of cornification and triglyceride synthesis genes. *BMC Genomics*. 2013; 14:169.
27. Goossens, Kate; Ward, Alister; Lowenthal, John; Bean, Andrew. Chicken interferons, their receptors and interferon-stimulated genes. *Developmental and Comparative Immunology*. 2013; 41(3):370-376.

28. Guo, Pengju; Thomas, Jesse; Bruce, Matt; Hinton, Tracey; Bean, Andrew; Lowenthal, John. The chicken TH1 response: Potential therapeutic applications of ChIFN-g. *Developmental and Comparative Immunology*. 2013; 41(3):389-396.
29. Hamilton, Keith; Pavade, Gounalan; Claes, Filip; Dauphin, Gwenaëlle; Daniels, Peter. Animal influenza research needs: protecting humans, animals, food, and economies. *Influenza and other respiratory viruses*. 2013; 7(Suppl. 2):34-36.
30. Hayward, Joshua; Tachedjian, Mary; Cui, Jie; Field, Hume; Holmes, Edward C; Wang, Linfa; et al. Identification of diverse full-length endogenous betaretroviruses in megabats and microbats. *Retrovirology*. 2013; 10(1):19.
31. Henning, Joerg; Morton, J; Wibawa, Hendra; Yulianto, D; Usman, Tri Bhakti; Prijono, W; et al. Incidence and risk factors for H5 highly pathogenic avian influenza infection in flocks of apparently clinically healthy ducks. *Epidemiology and Infection*. 2013; 141(2):390-401.
32. Islam, Mohammad Saiful; Kouzani, Abbas; Dai, Xiujuan; Michalski, Wojtek; Gholamhosseini, H. Design and analysis of a multilayer localized surface plasmon resonance graphene biosensor.. *Journal of Biomedical Nanotechnology*. 2013; 8(3 .):380-393.
33. Jones, Kate; Karpala, Adam; Hirst, Bevan; Jenkins, Kristie; Tizard, Mark; Pereira, Candida; et al. Visualising single molecules of HIV-1 and miRNA nucleic acids. *BMC Cell Biology*. 2013; 14(4):21.
34. Keeling, Suzanne Elizabeth; Brosnahan, Cara; Johnston, Colin; Wallis, Reuben; Gudkovs, Nicholas; McDonald, Wendy Leanne. Development and validation of a real-time PCR assay for the detection of *Aeromonas salmonicida*.. *Journal of Fish Diseases*. 2013; 36(5):495-503.
35. Konsak, Barb; Stanley, Dragana; Haring, Volker; Geier, Mark; Hughes, Robert; Howarth, Gordon; et al. Identification of differential duodenal gene expression levels and microbiota abundance correlated with differences in energy utilisation in chickens. *Animal Production Science*. 2013; 53:1269-1275.
36. Lambeth, Luke; Cummins, David; Doran, Tim; Sinclair, Andrew; Smith, Craig. Overexpression of Aromatase alone is sufficient for ovarian development in genetically male chicken embryos. *PLoS ONE*. 2013; 8(6):e68362.
37. Lima, Paula; Harris, James; Cook, Mat. Exploring RNAi as a therapeutical strategy for controlling disease in aquaculture. *Fish and Shellfish Immunology*. 2013; 34(3):729-743.
38. Marsh, Glenn; Virtue, Elena; Smith, Ina; Todd, Shawn; Arkinstall, Rachel; Frazer, Leah; et al. Recombinant Hendra viruses expressing reporter genes retain pathogenicity in ferrets. *Virology journal*. 2013; 10:95.
39. McCaskill, Jana; Marsh, Glenn; Monaghan, Paul; Wang, Linfa; Doran, Tim; McMillan, Nigel. Potent Inhibition of Hendra Virus Infection via RNA Interference and Poly I:C Immune Activation. *PLoS ONE*. 2013; 8(5):e64360.
40. McColl, Ken; Clarke, Brian; Doran, Tim. Role of genetically engineered animals in future food production. *Australian Veterinary Journal*. 2013; 91(3):113-117.
41. Ng, Justin; Baker, Michelle. Bats and bat-borne diseases: a perspective on Australian megabats. *Australian Journal of Zoology*. 2013; 61:48-57.

42. Olival, Kevin J; Islam, Ariful; Yu, Meng; Anthony, Simon; Epstein, Jonathan; Khan, Shahneaz Ali; et al. Ebola Virus Antibodies in Fruit Bats, Bangladesh. *Emerging Infectious Diseases*. 2013; 19(2):4.
43. Palacios, Gustavo; Forrester, Naomi; Nasar, Farooq; Savji, Nazir; Travassos da Rosa, Amelia; Guzman, Hilda; et al. Characterization of Farmington virus, a novel virus from birds that is distantly related to members of the family Rhabdoviridae. *Virology Journal*. 2013; 10:e219.
44. Pallister, Jackie; Klein, Reuben; Arkinstall, Rachel; Haining, Jessica; Long, Fenella; White, John; et al. Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. *Virology Journal*. 2013; 10:1-7.
45. Pant, Ganesh; Lavenir, Rachel; Wong, Frank; Certoma, Andrea; Larrous, Florence; Bhatta, D.R.; et al. Recent emergence and spread of a phylogenetic lineage of rabies virus in Nepal. *PLoS Neglected Tropical Diseases*. 2013; 7(11):11.
46. Paradkar, Prasad; Walker, Peter. Why don't mozzies get a fever?. *Australasian Science*. 2013; 34:16-18.
47. Peel, Alison; McKinley, Trevelyan; Baker, Kate; Barr, Jenn; Cramer, Gary; Hayman, David; et al. Use of cross-reactive serological assays for detecting novel pathogens in wildlife: Assessing an appropriate cutoff for henipavirus assays in African bats. *Journal of Virological Methods*. 2013; 193(2):295-303.
48. Peel, Alison; Sargan, David; Baker, Kate; Hayman, David; Barr, Jenn; Cramer, Gary; et al. Continent-wide panmixia of an African fruit bat facilitates transmission of potentially zoonotic viruses. *Nature Communications*. 2013; 4:2770.
49. Penrith, Mary-Louise; Vosloo, Wilna; Jori, Ferran; Bastos, Arminda Duarte Slager. African swine fever virus eradication in Africa. *Virus Research*. 2013; 173(1):228-46.
50. Ranasinghe, Charani; Trivedi, S; Stambas, John; Jackson, RJ. Unique IL-13R α 2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8⁺ T-cell avidity and protective immunity. *Mucosal Immunology*. 2013; 6(6):1068-1080.
51. Rockman, Steve; Brown, Lorena; Barr, Ian; Gilbertson, Brad; Lowther, Sue; Kachurin, Anatoly; et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunised with seasonal influenza vaccine. *Journal of Virology*. 2013; 87(6):3053-3061.
52. Sendow, Indrawati; Field, Hume; Ratnawati, Atik; Adjid, RM Abdul; Saepulloh, Muharam; Breed, Andrew; et al. Status Infeksi Virus Hendra Pada Kalong (*Pteropus* spp.) di Pontianak, Kalimantan Barat dan Manado, Sulawesi Utara (Hendra Virus Infectious Status on Flying Fox (*Pteropus* spp) in Pontianak West Kalimantan and Manado-North Manado). *Jurnal Biologi Indonesia*. 2013; 9(1):31-38.
53. Sendow, Indrawati; Ratnawati, Atik; Taylor, Trevor; Abdul Adjid, RM; Saepulloh, Muharam; Barr, Jenn; et al. Nipah virus in the fruit bat *Pteropus vampyrus* in Sumatera, Indonesia. *PLoS ONE*. 2013; 8(7):e69544.
54. Short, Kirsty; Habets, Marrit; Payne, Jean; Reading, Patrick; Diavatopoulos, Dimitri; Wijburg, Odilia. Influenza A Virus induced bacterial otitis media is independent of virus tropism for α 2,6-linked sialic acid. *Virology Journal*. 2013; 10:128.

55. Slocombe, Ron; Christina, McCowan; Wang, Jianning; Holz, Peter. Avian pox in crimson rosellas (*Platycercus elegans*) in southern Australia. *Avian Pathology*. 2013; 42(2):147-150.
56. Smith, Ina; Wang, Linfa. Bats and their virome: an important source of emerging viruses capable of infecting humans. *Current Opinion in Virology*. 2013; 3(1):84-91.
57. Speare, R; Luly, J; Reimers, J; Durrheim, D; Lunt, Ross. Antibodies to Australian bat lyssavirus in an asymptomatic bat carer. *Internal Medicine Journal*. 2013; 43(11):1256-1257.
58. Stanley, Dana; Geier, Mark; Denman, Stuart; Haring, Volker; Crowley, Tamsyn; Hughes, Robert; et al. Identification of chicken intestinal microbiota correlated with the efficiency of energy extraction from feed. *Veterinary Microbiology*. 2013; 164(1-2):85-92.
59. Stanley, Dana; Watson-Haigh, Nathan; Cowled, Chris; Moore, Rob. Genetic architecture of gene expression in the chicken. *BMC Genomics*. 2013; 14:13.
60. Stewart, Cameron; Keyburn, Anthony; Deffrasnes, Celine; Tompkins, Mark. Potential directions for chicken immunology research. *Developmental and Comparative Immunology*. 2013; 41(3):463-468.
61. Stewart, Cameron; Marsh, Glenn; Jenkins, Kristie; Deffrasnes, Celine; Bean, Andrew; Wang, Linfa; et al. Promotion of Hendra virus replication by microRNA-146a. *Journal of Virology*. 2013; 87(7):3782-3791.
62. Stewart, Cameron; Marsh, Glenn; Jenkins, Kristie; Gantier, Michael; Tizard, Mark; Middleton, Deborah; et al. Promotion of Hendra virus replication by MicroRNA 146a. *Journal of Virology*. 2013; 87(7):3782-3791.
63. Tyack, Scott; Jenkins, Kristie; O'Neil, Terri; Wise, Terry; Morris, Kirsten; Bruce, Matt; et al. A new method for producing transgenic birds via direct in vivo transfection of Primordial Germ Cells. *Transgenic research*. 2013; 22(6):1257-1264.
64. Vasilakis, Nikos; Widen, Steve; Mayer, Sandra; Seymour, Robert; Wood, Thomas; Popov, Vsevolov; et al. Niakha virus: A novel member of the family Rhabdoviridae isolated from phlebotomine sandflies in Senegal. *Virology*. 2013; 444:80-89.
65. Vasilakis, Nikos; Wilden, Steve; Travassos da Rosa, Amelia; Wood, Thomas; Walker, Peter; Edward, Holmes; et al. Malpais Spring virus is a new species in the genus Vesiculovirus. *Virology Journal*. 2013; 10:e69.
66. Vincent, Amy; Awada, Lina; Brown, Ian; Chen, Hualan; Claes, Filip; Dauphin, Gwenaelle; et al. Review of influenza A virus in swine worldwide: a call for increased surveillance and research. *Zoonoses and Public Health*. 2013; Online early:online.
67. Vosloo, Wilna. Foot-and-mouth disease: a persistent threat. *Microbiology Australia*. 2013; March:18-21.
68. Wagner, Josef; Skinner, Narelle; Catto-Smith, A.; Cameron, Donald; Michalski, Wojtek; Visvanathan, Kumar; et al. TLR4, IL10RA, and NOD2 mutation in paediatric Crohn's disease patients: an association with *Mycobacterium avium* subspecies paratuberculosis and TLR4 and IL10RA expression.. *Medical Microbiology and Immunology*. 2013; 202(4):267-276.
69. Walker, Peter. Bovine ephemeral fever – resurgence of a climate-sensitive vector-borne disease. *Microbiology Australia*. 2013; 34:41-42.
70. Wang, Linfa. Nyamiviridae: Proposal for a new family in the order Mononegavirales. *Archives of Virology*. 2013; 158(10):2209-2226.

71. Wang, Linfa. Thank you to Virology Journal's peer reviewers in 2012. *Virology Journal*. 2013; 10(1):44.
72. Wang, Linfa; Michalski, Wojtek; Yu, Meng; Pritchard, Ian; Crameri, Gary; Shiell, Brian; et al. A novel P/V/C gene in a new Paramyxoviridae virus which causes lethal infection in humans, horses and other animals.. *Journa of Virology*. 2013; 72(2):1482-1490.
73. Wibawa, Hendra; Bingham, John; Nuradji, Hari; Lowther, Sue; Payne, Jean; Harper, Jenni; et al. The pathobiology of two Indonesian H5N1 avian influenza viruses representing different clade 2.1 sublineages in chickens and ducks. *Comparative Immunology Microbiology Infectious Diseases*. 2013; 36(2):175-191.
74. Wynne, James; Di Rubbo, Antonio; Shiell, Brian; Beddome, Gary; Cowled, Chris; Peck, Grant; et al. Purification and Characterisation of Immunoglobulins from the Australian Black Flying Fox (*Pteropus alecto*) Using Anti-Fab Affinity Chromatography Reveals the Low Abundance of IgA. *PLoS ONE*. 2013; 8(1):e52930.
75. Xuxia, Yan; Corrine, Porter; Hardy, Simon; Steer, David; Smith, Ian; Quinsey, Noelene; et al. Structural and functional analysis of the pore-forming toxin NetB from *Clostridium perfringens*.. *MBio*. 2013; 4(1):e00019-13.
76. Zhang, Guojie; Cowled, Chris; Shi, Zhengli; Huang, Zhiyong; Bishop-Lilly, Kimberly; Fang, Xiaodong; et al. Comparative Analysis of Bat Genomes Provides Insight into the Evolution of Flight and Immunity. *Science*. 2013; 339(6118):456-460.
77. Zhou, Li; Xu, Jie; Chen, Zhenhai; Gao, Xiudan; Wang, Linfa; Sakamoto, Kaori; et al. The L Gene of J Paramyxovirus (JPV) Plays a Critical Role In Viral Pathogenesis. *Journal of Virology*. 2013; 187(23):12990-12998.
78. Zhou, Peng; Cowled, Chris; Wang, Linfa; Baker, Michelle. Bat Mx1 and OAS1, but not PKR are highly induced by bat interferon and viral infection. *Developmental and Comparative Immunology*. 2013; 40(3-4):240-247.
79. Zinsstag, Jakob; Jeggo, Martyn; Schelling, Esther; Bonfoh, Bassirou; Waltner-Toews, David; Lelii, Stefano; et al. Convergence of Ecohealth and One Health. *EcoHealth*. 2013; 9:371-373.

Conference papers/Conference proceedings

1. Audsley, Michelle; Marsh, Glenn; Tachedjian, Mary; Wang, Linfa; Jans, David; Moseley, Greg. Novel insights into the divergent mechanisms of paramyxovirus immune evasion. In: XV International Conference on Negative Strand Viruses; 16-21 June 2013; Spain. XV International Conference on Negative Strand Viruses; 2013. 125.
2. Claes, Filip; Sonnberg, Stephanie; Brown, Ian; Morrissy, Chris; Daniels, Peter. Scientific update on Avian Influenza A(H7N9) - animal health aspects: presentation to the Technical and Policy Discussion on the prevention and control of avian influenza A (H7N9) in Asia. In: Technical and Policy Discussion on the Prevention and Control of Avian Influenza A (H7N9) in Asia; 24-25 June 2013; Bangkok. The workshop; 2013. 1.
3. Corbeil, Serge. Biotechnology and the diagnosis and surveillance of aquatic animal pathogens. In: OIE, editor/s. Aquatic animal health programmes their benefits for global food security: Proceedings of the OIE Conference on Aquatic Animal Health; 28-30 June, 2011; Panama City, Panama. Paris: OIE; 2013. 161-169.

4. Corbeil, Serge. CSIRO-IFREMER: Collaborative studies on molluscs pathogens.. In: Joanne Slater, editor/s. Second Australasian Scientific Conference on Aquatic Animal Health; 8-12 July 2013; Cairns, QLD. FRDC; 2013. 1.
5. Corbeil, Serge. Mollusc diseases of significance in Australia and their (molecular) diagnosis.. In: Mollusc Diagnostic Workshop; 21-10-2013 to 24-10-2013; Geelong. CSIRO; 2013. 27.
6. Cramer, Sandra; Holmes, Clare; Leis, Andrew; Smith, Ina; Shan, songhua; Lehmann, Debra; et al. A novel orthomyxovirus in Muscovy ducks – electron microscopy reveals structural resemblance to arenaviruses.. In: APMC10/ICONN2012/ACMM22; Feb 2012; Perth WA. The Conference; 2013. 1.
7. Cramer, Sandy; Van Huezen, Rob; Borg, Anna; Miller, Dan; Leis, Andrew; Morrissey, John; et al. Case study - Using the CSIRO DAP for managing AAHL Microscopy data.. In: Computational and Simulation Sciences and eResearch Annual Conference; 22nd March 2013; The Langham Hotel, Melbourne. The Conference; 2013. 1.
8. Daniels, Peter. Climate Change, Animal Health and Bigger Issues. In: Australian and New Zealand College of Veterinary Scientists SCIENCE WEEK 2013; 11-13 July 2013; Gold Coast. ANZCVS; 2013. 1.
9. Daniels, Peter. Climate change, animal health and bigger issues. In: Australian and NZ College of Veterinary Scientists, editor/s. 2013 College Science Week Scientific Meeting; 11–13 July 2013; QT Gold Coast, Surfers Paradise. Australian and NZ College of Veterinary Scientists; 2013. 38.
10. Daniels, Peter. Global Animal Surveillance Networks: OFFLU. In: International Influenza Networks Meeting; 14-16 January 2013; Scottsdale, Arizona. APHL; 2013. 1.
11. Daniels, Peter. Inadequate Surveillance for Emerging Zoonotic Influenza in Animal Populations. In: Communicable Disease Control (CDC) Conference; 19-20 March 2013; Canberra. Communicable Disease Network; 2013. 1.
12. Daniels, Peter. Investigations and management of emerging zoonoses in Australia and Southeast Asia. In: Certificate One Health Program; 18/05/2013; Gainesville, Florida. The Program; 2013. 1.
13. Daniels, Peter. Investigations and management of emerging zoonoses. In: University of Adelaide; 14 October 2013; Adelaide. University of Adelaide; 2013. 1.
14. Daniels, Peter. Lessons learned from the international experience of H5N1 influenza. In: One Health Workshop; 24-25 Oct 2013; Canberra. PHAA and NCEPH; 2013. 1.
15. Daniels, Peter. Managing the pandemic public health threats from animal agriculture. In: 4th Sustainable Animal Agriculture Conference for Developing Countries (SAADC); 27-31 July 2013; Lanzhou, Gansu province, China. 4th Sustainable Animal Agriculture Conference for Developing Countries (SAADC); 2013. 25-30.
16. Daniels, Peter. Recent experiences of the Australian Animal Health Laboratory with emerging zoonoses in Australia and Southeast Asia - A presentation at KSU. In: KSU College of Veterinary Medicine; 13/05/2013; Manhattann, Kansas. KSU; 2013. 1.
17. Daniels, Peter. Recent experiences of the Australian Animal Health Laboratory with emerging zoonoses in Australia and Southeast Asia. In: AMES Iowa NSVL Presentation; 10 May 2013; Ames, Iowa. NSVL; 2013. 1.
18. Daniels, Peter. What Needs to be Improved for Seasonal and Pandemic Influenza Surveillance, Preparedness and Response? Animal Health Issues. In: International Influenza Networks Meeting; 14-16 January 2013; Scottsdale, Arizona. APHL; 2013. 1.

19. Daniels, Peter. What can be done to manage catastrophic human disease threats from farmed animals?. In: 2nd GRF One Health Summit 2013; 17-20 November 2013; Davos, Switzerland. 2nd GRF One Health Summit 2013; 2013. 0.
20. Daniels, Peter; Wang, Jianning; Lunt, Ross; Meehan, Brian; Pritchard, Ian; Ritson-Bennett, Noel; et al. Diagnostics for surveillance, response, and recovery. Bluetongue viruses in sheep, cattle, and deer. In: USDA Gap Analysis and Countermeasures Assessment Orbiviruses Workshop; 14-16 May 2013; USDA Centre for Grain and Animal Health Research, Manhattan, Kansas. USDA; 2013. 1.
21. Daniels, Peter; Wong, Frank; O'Dea, Mark; McCullough, Sam; Barr, Ian. Surveillance of livestock for the next pandemic influenza: Lessons from influenza in pigs. In: ISIRV International Symposium; 7-8 March 2013; Dublin, Ireland. ISIRV; 2013. 1.
22. Edwards, Steve. Lifecycle cost finding for biocontainment facilities: material, operations, staffing. In: The 2013 international Conference on Biocontainment Facilities; 18-19 March 2013; San Diego. The 2013 international Conference on Biocontainment Facilities; 2013. 1.
23. Gough, Tamara; Goossens, Kate; Bruce, Matt; Harvey, Gemma; Wilson, Susanne; Ford, Mark; et al. Potential use of chicken interferon lambda as a novel vaccine adjuvant. In: IVIS 2013; August 2013; Milan. The Conference; 2013. 1.
24. Gough, Tamara; Goossens, Kate; Bruce, Matt; Harvey, Gemma; Wilson, Susanne; Ford, Mark; et al. Potential use of chicken interferon lambda as a novel vaccine adjuvant. In: Lorne Infection and Immunity Conference.; 20th-22nd February 2013; Lorne Vic.. The Conference; 2013. 1.
25. Graham, Kerryne; Durr, Peter; Van Klinken, Riëks. Modelling the risk of long-distance wind-borne spread of pests and pathogens The TAPPAS application - taking GIS-based research into operational use. In: GeoVet 2013; 21-08-2013; London, UK. CSIRO; 2013. 1.
26. Green, Diane; Pallister, Jackie; Williams, Catherine; White, John; Monaghan, Paul. Cell type affects Hendra virus protein trafficking.. In: Australian Virology Society Meeting; 8-11 December, 2013; Queenstown, New Zealand. AVS; 2013. 1.
27. Harper, Jenni; Payne, Jean; Bingham, John; Middleton, Deborah. Comparative pathology of Hendra virus: The search for an in vivo laboratory model.. In: National Histology Conference; 27-28 April 2013; Melbourne, Vic. National Histology Conference Group; 2013. 1.
28. Hinton, Tracey; Grusche, Felix; Acharya, Durga; Waddington, Lynne; Monaghan, Paul; Shi, Shuning; et al. Bicontinuous cubic phase nanoparticle lipid chemistry affects toxicity in cultured cells. In: 10th International Conference on Nanosciences & Nanotechnologies (NN13); 9-12 July, 2013; Thessaloniki, Greece. NANOTECHNOLOGY 2013; 2013. 2 p.
29. Lawless, Nathan; Reinhardt, Timothy; Bryan, Kenneth; Baker, Mike; Pesch, Bruce; Zimmerman, Duane; et al. Simultaneous NGS-based profiling of microRNA and mRNA expression in an in vivo *Streptococcus uberis* challenge model reveals that microRNAs are key amplifiers of monocyte inflammatory response networks and repressors of metabolism. In: ISAFG, editor/s. 5th Symposium on Animal Functional Genomics - ISAFG 2013; 9-11 Sept 2013; Guarujá, Brazil. ISAFG; 2013. 1.
30. Leis, Andrew; Oiseth, Sofia; Cramer, Sandra; Lundin, Leif. Visualization of carrageenan hydrogels by electron tomography. In: 2013 International Symposium on Computational Models for Life Sciences; 27-29 Nov 2013; Sydney. AIP Publishing; 2013. 206-213.

31. Leis, Andrew; Oiseth, Sofia; Cramer, Sandy; Lundin, Leif. Visualisation of polysaccharide hydrogels at the nanoscale. In: 26th New Zealand Conference on Microscopy; 12-15th February, 2013; Christchurch, New Zealand. Microscopy Society of New Zealand; 2013. 1.
32. Lewis, Nicola; Russell, CA; Burke, DF; Brown, Ian; Chen, Hualan; Claes, Filip; et al. Quantifying the global antigenic and genetic evolution in swine influenza A viruses and evaluating the relative zoonotic potential to humans. In: Options for the Control of Influenza VIII; 5-10 September 2013; Cape Town, South Africa. International Society for Influenza and Other Respiratory Diseases (ISIRV); 2013. 2.
33. Loh, Mai Hlaing; Carlile, Gemma; Morrissy, Chris; Eagles, Debbie; McCullough, Sam; Watson, James; et al. The challenges of establishing and conducting proficiency testing programs in South East Asian countries. In: Australian Association of Veterinary Laboratory Diagnosticians; 28th - 29th of November 2013; CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia. Australian Association of Veterinary Laboratory Diagnosticians; 2013. 1.
34. Marsh, Glenn; Wang, Linfa. Cedar Virus: a novel Henipavirus isolated from Australian bats.. In: 15th International Negative Strand Virus Meeting; 16-21 June; Granada Spain. Spain: 15th International Negative Strand Virus Meeting; 2013. 149.
35. Marsh, Glenn; Wang, Linfa. Cedar virus: A novel henipavirus isolated from Australian bats. In: XV international Conference on Negative Strand Viruses; 16-21 June 2013; Spain. XV international Conference on Negative Strand Viruses; 2013. 149.
36. McCullough, Sam. Australian Animal Health Laboratory (Geelong) - its role and its links to the PICTs. In: 15th Australasia/Oceania CVA Regional Conference; 2-6 Sept 2013; Fiji. 15th Australasia/Oceania CVA Regional Conference; 2013. 0.
37. McNabb, Leanne; Lunt, Ross; Ritson-Bennett, Noel; Carlile, Gemma; Loh, Mai Hlaing; Zalunardo, Michael; et al. Development of a Foot and Mouth Disease (FMD) 3ABC ELISA kit.. In: Ninth Annual Meeting of the Australian Association of Veterinary Laboratory Diagnosticians; 28-29th November, 2013; CSIRO AAHL, Geelong, Victoria. Peter Kirkland; 2013. 1.
38. Middleton, Deborah. The path to a Hendra Virus vaccine for horses chance favours only the prepared mind Pastuer 1854. In: The 31st meeting of the European Society and College of Veterinary pathologists; 4-7 Sept 2013; London. ECVP; 2013. 31.
39. Mohr, Peter. Evaluation of Megalocytivirus molecular tests. In: 3rd Aquatic Animal Health Technical Forum; 20-22nd March 2013; Adelaide. CSIRO; 2013. 1.
40. Mohr, Peter; Moody, Nick; Hoad, John; Williams, Nette; Anderson, Ian; Crane, Mark. Detection of a new genotype of the yellow head complex of viruses in *Penaeus monodon*. In: Australian Association of Veterinary Laboratory Diagnosticians; 28-29 November 2013; Australian Animal Health Laboratory. AAVLD; 2013. 1.
41. Mohr, Peter; Moody, Nick; Hoad, John; Williams, Nette; Anderson, Ian; Crane, Mark. Detection of a new genotype of the yellow head complex of viruses in *Penaeus monodon*. In: Marc Crane, editor/s. Second Australasian Scientific Conference on Aquatic Animal Health; 8-12 July 2013; The Pullman Reef Hotel, Cairns. FRDC; 2013. 1.
42. Moody, Nick. Mollusc disease diagnosis: Identification of diagnostic problems in Australia. In: KBBE Workshop on Mollusc Disease Diagnosis; 21-24 October, 2013; Geelong, Victoria, Australia. CSIRO; 2013. 22.

43. Moody, Nick. Mollusc disease diagnosis: Quality assurance systems in diagnostic laboratories in Australia. In: KBBE Workshop on Mollusc Disease Diagnosis; 21-24 October, 2013; Geelong, Victoria, Australia. CSIRO; 2013. 13.
44. Moody, Nick; Mohr, Peter; Boyle, David; Hick, Paul; Kirkland, Peter; Crane, Mark. OsHV-1 in Pacific oysters in NSW – molecular detection and partial characterisation. In: Mark Crane, editor/s. The Second Australasian Scientific Conference on Aquatic Animal Health; 8 July - 12 July 2013; Cairns, QLD. FRDC; 2013. 1.
45. Morrissy, Chris; Juzva, Susan; Meehan, Brian. Current Disease Situation CSF PRRS ASF. In: Regional Laboratory Network Training on Diagnostic and Characterisation of African Swine Fever, Classical Swine Fever and Porcine Reproductive and Respiratory Syndrome; 27-31 August 2012; Regional Animal Health Office No. 6, Ho Chi Minh City, Viet Nam. Mr Chris Morrissy; 2013. 32.
46. Pant, Ganesh; Lavenir, Rachel; Wong, Frank; Certoma, Andrea; Larrous, F.; Bhatta, D.R.; et al. Recent Emergence and spread of an Arctic-related phylogenetic lineage of Rabies in Nepal. In: 15th International Negative Strand Virus meeting; 16-21 June 2013; Granada, Spain. 15th International Negative Strand Virus meeting; 2013. 1.
47. Pant, Ganesh; Lavenir, Rachel; Wong, Frank; Certoma, Andrea; Larrous, Florence; Bhatta, D.R.; et al. Recent Emergence And Spread Of A Phylogenetic Lineage Of Rabies Virus In Nepal. In: European Congress of Virology; 11-14 September 2013; Lyon, France. European Congress of Virology; 2013. 1.
48. Pant, Ganesh; Lavenir, Rachel; Wong, Frank; Certoma, Andrea; Larrous, Florence; Bhatta, D.R.; et al. Recent Emergence and Spread of a Phylogenetic Lineage of Rabies Virus in Nepal. In: International meeting on microbial epidemiological markers; October 2-5 2013; Paris. The Conference; 2013. 1.
49. Pant, Ganesh; Lavenir, Rachel; Wong, Frank; Certoma, Andrea; Larrous, Florence; Bhatta, Dwij; et al. Recent Emergence and Spread of a Phylogenetic Lineage of Rabies Virus in Nepal. In: 15th International negative strand virus meeting, editor/s. 15th International negative strand virus meeting; 16-21 June 2013; 15th International negative strand virus meeting. 15th International negative strand virus meeting; 2013. 214.
50. Roennfeldt, Ruben-Lee; Moody, Nick; Heine, Hans; Boyle, David; Crameri, Sandra; Leis, Andrew; et al. The development of diagnostic assays for the detection of Zooplankton Invertebrate Iridescent viruses in the mesozooplankton. In: ASMA2013; 7-11 July 2013; QLD. ASMA2013; 2013. 193.
51. Rohringer, Andreas; Goossens, Kate; Ward, Alister; Bean, Andrew. The chicken IFN- λ Receptor Complex. In: International Veterinary Immunology Symposium; 28th August - 1st September 2013; Milan , Italy , Europe. IVIS; 2013. 1.
52. Shiell, Brian; Colgrave, Michelle; Michalski, Wojtek; Snelling, Hayley; Broder, Christopher. Determination of glycan composition and site occupancy of glycoproteins by mass spectrometry. In: David Hills (Scientific Director), editor/s. Mass Spec 2013; 6-7 March 2013; Biopolis, Singapore. Mass Spec 2013 Conference; 2013. 18.
53. Stevens, Vicky; Eagles, Debbie; Wong, Frank. Annual update of avian influenza reference laboratory activities at AAHL. In: Australasian Veterinary Poultry Association; 3 - 4 October 2013; Adelaide. AVPA; 2013. 2.
54. Stewart, Cameron; Marsh, Glenn; Jenkins, Kristie; Tizard, Mark; Gantier, Michael; Middleton, Deborah; et al. Promotion of Hendra virus replication by microRNA 146a.. In: IVIS 2013; August 2013; Milan. The Conference; 2013. 1.

55. Stewart, Cameron; Marsh, Glenn; Rootes, Chris; Wang, Linfa; Bean, Andrew; Lowenthal, John; et al. Host genes crucial for Hendra virus replication. In: RNAi Australia; 18 - 19 July 2013; Melbourne, Vic.. Victorian Platform Technologies Network; 2013. 1.
56. Swayne, David; Daniels, Peter; Dauphin, Gwenaelle; Hamilton, Keith; Mumford, Elizabeth. Filling Gaps For Seasonal And Pandemic Influenza: Current Data And Future Directions - Animal/Human Interface Priorities For Better Information. In: International Influenza Networks Meeting; 14-16 January 2013; Scottsdale, Arizona. APHL; 2013. 1.
57. Wang, Jianning; Yu, Meng; Ha, Wendy; Rootes, Chris; Wise, Terry; Cramer, Sandra; et al. Identification of a novel Bunyavirus using next generation sequencing. In: 16th International Symposium of the World Association of Veterinary Laboratory Diagnosticians; 5-8 June 2013; Berlin, Germany. Deutsche Veterinärmedizinische Gesellschaft; 2013. 99.
58. Ward, Phil; Oliver, Yvette; Hollamby, Nadine. What to do with a wet summer: summer weeds, soil water, and subsequent crop yield. In: Ian Longson, editor/s. Perth Crop Updates; February 25-26, 2013; Perth. Grains Industry Western Australia; 2013. 4.
59. Watson, James. STARS - Surveillance - Integrating data across the Australian Laboratory Network.. In: USAHA/AAVLD Committee on Animal Health Surveillance and Information Systems; 17-23 October 2013; San Deigo. USAHA/AAVLD Committee on Animal Health Surveillance and Information Systems; 2013. 1.
60. Wong, Frank. Influenza activities at AAHL. In: 2013 Consuls General AAHL Tour Presentation; 8/05/2013; Australian Animal Health Laboratory, Geelong. CSIRO; 2013. 1.
61. Wong, Frank; Barr, Ian; Smith, David; Williams, David; Davies, Kelly; Stevens, Vicky; et al. Coordinating worldwide surveillance for influenza in pigs - Australia and Oceania update. In: OFFLU Swine Influenza Group Technical Meeting 2013; 16/04/2013; FAO Headquarters, Rome. OFFLU and FAO; 2013. 11.
62. Wong, Frank; Meehan, Brian; Wang, Jianning; Carlile, Gemma; Loh, Mai Hlaing; Cooke, Julie; et al. Animal health aspects of avian influenza A(H7N9) and regional veterinary laboratory preparedness in Southeast Asia. In: 9th Australian Influenza Symposium; 3-4 October 2013; The University of Sydney, Sydney, Australia. WHO Collaborating Centre for Reference and Research on Influenza, Melbourne; 2013. 1.
63. Zuelke, Kurt. How epidemiology and animal health science can help identify and inform policy options. In: Livestock disease policies, building bridges between science and economics; 3-4 June 2013; Paris. OECD; 2013. 13.

Books/Book chapters

1. Daniels, Peter. OIE Collaborating Centre Reports - New and Emerging Diseases - Activities in 2012. In: Paris, France: OIE; 2013. 2.
2. Pitt, John; Wild, Christopher; Baan, Robert; Gelderblom, Wenzel; Miller, David; Riley, Ronald; et al. Improving Public Health through Mycotoxin Control. IARC, Lyon, France: International Agency for Research on Cancer; 2013.
3. Wandeler, Alexander; Bingham, John; Meslin, François-Xavier. Dogs and Rabies. In: Calum McPherson, François-Xavier Meslin, Alexander Wandeler, editor/s. Dogs, Zoonoses and Public Health. CABI; 2013. 63-90.

Reports

1. Crane, Mark. OIE Reference Laboratory Reports Activities in 2012 - Infection with abalone herpes-like virus. Paris: OIE; 2013. csiro:EP136902
2. Daniels, Peter. OIE Collaborating Centre Reports - Laboratory capacity Building - Activities in 2012. OIE; 2013. csiro:EP131242
3. Daniels, Peter. OIE Reference Laboratory Reports Activities in 2012 - Bluetongue. Paris: OIE; 2013. csiro:EP136121
4. Daniels, Peter. OIE Reference Laboratory Reports Activities in 2012 - Nipah and Hendra Virus Diseases. Paris: CSIRO; 2013. csiro:EP136120
5. Daniels, Peter; Melville, Lorna; Eagles, Debbie. Bluetongue Viruses: Overview of Virological and Epidemiological Issues for the Husbandry in Sheep Northern Australia: A brief discussion paper. AHC: AHC; 2013. csiro:EP135886
6. Hyatt, Alexander. OIE Reference Laboratory Reports Activities in 2012- Infection with *Batrachochytrium dendrobatidis*. Paris: OIE; 2013. csiro:EP136900
7. Selleck, Paul. OIE Reference Laboratory Reports Activities in 2012- Avian Influenza. OIE: OIE; 2013. csiro:EP136894
8. Selleck, Paul. OIE refernce Laboratory reports Activities 2012 - Newcastle Disease. Paris: OIE; 2013. csiro:EP136895
9. Whittington, Richard; Hyatt, Alexander. OIE Reference Laboratory Reports Activities 2012 - Ranavirus. Paris: OIE; 2013. csiro:EP136897
10. Whittington, Richard; Hyatt, Alexander. OIE Reference Laboratory Reports Activities 2012 - Epizootic Haematopoietic Necrosis. OIE: OIE; 2013. csiro:EP136896
11. Wong, Frank; Selleck, Paul; Durr, Peter; Morrissy, Chris; Allen, John. Final Report OFFLU Indonesia Project OSRO/INS/103/USA LoA3 (PR 47795) - Facilitation and implementation of laboratory training and studies on samples submitted as isolates of avian influenza viruses from Indonesia. OFFLU; 2013. csiro:EP131743

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures ¹⁶	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	Yes	Yes	No	No
(b) Exports of micro-organisms ¹⁷ and toxins	Yes	Yes	Yes	No
(c) Imports of micro-organisms ¹¹ and toxins	Yes	Yes	No	No
(d) Biosafety ¹⁸ and biosecurity ¹⁹	Yes	Yes	Yes	Yes

¹⁶ Including guidelines.

¹⁷ Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

In addition to the above summary, an overview of key Australian Government legislation relevant to the BWC is provided below:

Background

The following Australian Government legislation, regulations and other measures are relevant to this confidence-building measure. The Australia Government has a range of legislative and executive measures that ensure compliance with UN Security Council Resolution 1540 (2004).

Australia is fully committed to the work of the 1540 Committee in ensuring global implementation of this resolution. As well as legislation dedicated to Weapons of Mass Destruction (WMD), there is a considerable amount of health, safety and environmental legislation that control access to hazardous biological materials.

National Health Security Act 2007

The *National Health Security Act 2007* (NHS Act) was passed by the Australian Parliament in September 2007. It has two main operative parts: Part 2 of the Act enacts Australia's responsibilities under the International Health Regulations 2005 and formalises surveillance systems in Australia, while Part 3 establishes a regulatory scheme for biological agents of security concern. Part 3 of the NHS Act enables the Department of Health to regulate the handling of Security Sensitive Biological Agents (SSBAs). The NHS Act establishes a list of SSBAs, a National Register that is informed by mandatory reporting, purposes for which the SSBAs may be handled, security standards (physical, personnel, information management and transport) that must be met, exemptions from regulation, and an inspection scheme to monitor compliance.

Changes to the operational detail of the regulatory scheme continue to be made as the need arises. The NHS Act was amended in 2013 to include new provisions on temporary handlings of SSBAs, strengthening of the inspection scheme and strengthening of the requirements for handling biological agents suspected of being SSBAs.

Security Sensitive Biological Agent Standards

The SSBA Standards set out minimum requirements relating to physical security, personnel, information management, decontamination and inactivation, disposal and transport of SSBAs and biological agents suspected of being SSBAs. They include specific directions for dealing with biosecurity risks and establish a systematic approach to the management of the security of SSBAs. The SSBA Standards are comprised of normative requirements that are mandatory and informative statements to assist in meeting the normative statements. The SSBA Standards were amended in 2013 to align with changes to the NHS Act.

¹⁸ In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

¹⁹ In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

The SSBA Regulatory Scheme is further strengthened through a background checking scheme for personnel who handle SSBAs. Background checks, known as National Health Security Checks, consist of a national criminal history check against a list of disqualifying offences and a security assessment.

The SSBA Regulatory Scheme has a comprehensive inspection scheme for facilities handling SSBAs. Registered facilities that handle Tier 1 SSBAs are inspected every 18 months. Registered facilities that handle Tier 2 SSBAs are inspected every two years. Inspections of non-registered facilities and spot checks are undertaken as required. Inspections continue to show a high level of compliance.

Chemical Weapons (Prohibition) Act 1994 and associated regulations

This Act is administered by the Minister for Foreign Affairs, and statutory responsibilities are held by the Australian Safeguards and Non-Proliferation Office. The Act gives effect to Australia's obligations under the *Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on their Destruction*. The Act controls certain chemicals which may be used as weapons, including the natural toxins ricin and saxitoxin. The Act's general purpose criterion also applies to the hostile use of any chemical, including other toxins. The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

Crimes (Biological Weapons) Act 1976

This Act, which is administered by the Attorney-General, makes it unlawful for Australians to develop, produce, stockpile or otherwise acquire or retain microbial or other biological agents or toxins whatever their origin or method of production, of types and in quantities that have no justification for prophylactic, protective or other peaceful purposes; or weapons, equipment or means of delivery designed to use such agents or toxins for hostile purposes or in armed conflict. The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

Crimes (Biological Weapons) Regulations 1980

These Regulations specify the way in which substances acquired under the Act should be stored, disposed of and analysed.

Customs Act 1901 and Customs (Prohibited Exports) Regulations 1958

This Act is administered by the Minister for Immigration and Border Protection and the Minister for Defence. The *Customs (Prohibited Exports) Regulations 1958* prohibits the exportation from Australia of defence and dual-use goods listed in the Defence and Strategic Goods List (DSGL) without prior permission from the Minister for Defence or an authorised person. Under the regulations, the Minister for Defence may authorise in writing a person employed in the Department of Defence to approve exports of defence and dual-use goods listed on the DSGL. Applications to export goods listed in the DSGL are considered on a case-by-case basis against published policy

criteria to ensure exports of defence and dual-use goods are consistent with Australia's broader national interests and international obligations.

The DSGL is divided into two parts: Part 1 of the DSGL covers defence and related goods, which are those goods and technologies designed or adapted for use by armed forces or goods that are inherently lethal; Part 2 of the DSGL covers those goods that have a dual use. Dual-use goods comprise equipment and technologies developed to meet commercial needs, but which may be used either as military components or for the development or production of military systems or WMD. As such, Part 2 includes human pathogens and toxins, animal pathogens, plant pathogens and equipment capable of being used to develop biological weapons.

The DSGL is amended from time-to-time to reflect changes in the various multilateral non-proliferation and export control regimes of which Australia is a member.

Quarantine Act 1908 and associated regulations

The *Quarantine Act 1908* is administered by the Minister for Agriculture and the Minister for Health. The Act is designed to prevent the introduction of serious pests and diseases affecting humans, plants and animals into Australia. Accordingly, in conjunction with the *Biological Control Act* (see below), it controls the import into Australia of all biological material and may prohibit the import in some circumstances.

Those aspects of the Act that relate to human quarantine are administered by the Minister for Health. Those aspects of the Act that relate to plant and animal quarantine are administered by the Minister for Agriculture. All biological agents require prior permission to import. Under the provisions of section 13 of the Act, goods of biological origin, including human pathogenic microorganisms and toxins, may only be imported into Australia if approval has been given by a Director of Quarantine (Animal/Plant or Human). In giving approval, the Director may require that the importer adhere to certain conditions or requirements, including, but not limited to, the storage, transportation, distribution and disposal of the goods, the use to which the goods may be put, and the personnel authorised to handle or use the goods.

Import conditions vary depending on the nature of the organisms, and on the risks involved. High risk organisms such as serious pathogens of humans, animals and plants which might be considered as potential biological weapons would only be permitted under the most stringent, high security conditions. Very few such imports are approved, and generally those would be for diagnostic research in preparation for emergency responses to specific serious exotic disease incursions.

Penalties for the importation of controlled goods without a permit, and for breaches of permit requirements, are severe and may include a fine, imprisonment or both.

Biological Control Act 1984 and associated regulations

This Act is administered by the Minister for Agriculture. It provides powers additional to those of the Quarantine Act in order to regulate the release of biological agents for the control of pests, diseases and weeds. It primarily covers issues of compensation for the release of a biological control agent.

Gene Technology Act 2000 and associated regulations

This Act is administered by the Minister for Health and regulates dealings with genetically modified organisms (GMOs) to protect the health and safety of people and the environment. The legislation is administered by an independent statutory office holder, the Gene Technology Regulator, and provides a risk-based system for regulation of GMOs. There are also legislative provisions for accreditation of organisations, certification of physical containment facilities and extensive monitoring and enforcement powers.

All dealings with GMOs must be licensed by the Regulator, unless otherwise authorised under the legislation. Dealings include manufacture, import, transport or conducting experiments with GMOs. All licence applications are subject to case-by-case scientific risk assessment and risk management.

The legislation requires licensing for 'higher risk' GMOs, which would include those that could potentially be used as biological weapons or for other malicious purposes, including those that involve: modifications that may alter pathogenicity, virulence, host range or treatment of a microorganism; cloning or high expression of toxin genes; or animals, plants or fungi that are capable of secreting infectious agents as a result of the genetic modification. Work with such 'higher risk' GMOs is typically for medical research purposes and licence conditions include requirements that dealings be conducted in facilities certified by the Regulator to a specific physical containment (PC) level.

There are significant penalties for dealing with GMOs without a licence, and for breaches of licence conditions, which may include a fine, imprisonment or both.

Therapeutic Goods Act 1989 and associated regulations

The Therapeutic Goods Administration (TGA) is a division of the Australian Government Department of Health, and regulates therapeutic goods for human use under this Act. The Act covers the import, manufacture, supply and export of therapeutic goods, and includes pathogenic micro-organisms where these are included in vaccines for human use.

Prior to initial supply for human use, products must be entered in the Australian Register of Therapeutic Goods (the Register). Vaccines are registrable products, and undergo evaluation by the TGA prior to entry in the Register.

Weapons of Mass Destruction (Prevention of Proliferation) Act 1995 and associated regulations

The Act is administered by the Minister for Defence and complements the existing controls contained in the *Customs Act 1901* and the *Customs (Prohibited Exports) Regulations 1958*. The Act and the associated Regulations provide the legislative basis for controlling the movement of goods and services that will or may assist in the development of weapons of mass destruction (WMD) or systems capable of delivering such weapons. It prohibits the supply or export of goods (not otherwise controlled by the *Customs Act*) and/or the provision of services, in circumstances where the goods or services may be used to assist in the development, production, acquisition or

stockpiling of WMD, including biological weapons or their delivery systems. The prohibitions under the legislation apply where the person involved knows or suspects the connection with a WMD program, including a biological weapons program.

The Act applies extraterritorially as well as within Australia, covering the activities of Australian citizens or residents, as well as bodies incorporated in Australia. It provides a mechanism for exporters to obtain written guidance from the Government on the risk of a particular planned transaction contributing to a biological weapons program.

Defence Trade Controls Act 2012 and associated regulations

This Act is administered by the Minister for Defence. The *Defence Trade Controls Act 2012* introduces new controls on the supply and brokering of goods and technology listed on the Defence and Strategic Goods List (DSGL). The DSGL is divided into two parts. Part 1 covers defence and related goods, which are those goods and technologies designed or adapted for use by armed forces or goods that are inherently lethal, while Part 2 covers goods that have a dual use. As such, Part 2 includes human pathogens and toxins, animal pathogens, plant pathogens and equipment capable of being used to develop biological weapons. However, the controls listed in the Act are yet to commence operation and are currently the subject of further review. The offence provisions for the supply and brokering of controlled goods or technology will not commence until at least May 2015.

Guidelines to prevent the inadvertent supply of biological weapons-applicable plant, equipment, source cultures and expertise

The Guidelines are a non-statutory, non-proliferation measure, developed by the Department of Foreign Affairs and Trade, to raise the awareness of industry and researchers about the risk of inadvertent involvement in the biological weapons programs of other countries. The Guidelines have been circulated to biological industry, universities, relevant professional associations and government agencies.

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development programmes

In the interest of increasing transparency and openness, States parties shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

If so, States parties shall provide information on such programmes, in accordance with Form F.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

In addition to the following information, see [Attachment 4](#) for an explanation of research related to biological warfare defence in Australia.

1. Date of entry into force of the Convention for the State party.

5 October 1977

2. Past offensive biological research and development programmes:

- YES – NO

No

- Period(s) of activities

Not applicable

- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

Not applicable, but see Attachment 4.

3. Past defensive biological research and development programmes:

- YES – NO

Yes. Since 1994 Australia commenced a modest program of research into defence against toxins as warfare agents (see Attachment 4).

- Period(s) of activities

1994 onwards (see Attachment 4).

- Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

[See Attachment 4.](#)

**EXPLANATORY STATEMENT
RESEARCH AND DEVELOPMENT PROGRAMS RELATED TO
BIOLOGICAL WARFARE AND DEFENCE IN AUSTRALIA
SINCE 1 JANUARY 1946**

Between 1946 and 1994, Australia had no research and development program specifically aimed at defence against biological and toxin weapons. However, some methods for protection against chemical warfare agents could also be used to protect against biological agents. As Australia has had a longstanding research and development program to develop protection against chemical agents, it had, though only incidentally, also been involved in the development of means capable of offering some protection from biological weapons.

The position at the end of World War II

During World War II, Australia acquired a protective capability against chemical and biological warfare (CBW), which included the equipping of military units with protective clothing, respirators, detection apparatus and decontamination equipment. This capability was associated with the threat of chemical warfare, as almost all of the major combatants possessed chemical weapons.

Australia had no biological weapons and knew little about them. While a need for some defence against them was generally perceived, no major specific steps were taken to achieve this. The tendency was to regard chemical and biological weapons as a single category of threat, with biological weapons treated as the lesser element.

The situation from 1945 to the 1970s

In the late 1940s and 1950s, Defence committees assessed the need for defence against biological agents. The view adopted was that if biological threats arose, Defence authorities would co-opt staff from public health facilities that were trained in microbiology and biological sciences.

Australia also received limited information on biological defence from the United States of America, the United Kingdom and Canada through the Technical Cooperation Program (TTCP). Under the TTCP, there is provision for collaborative research on biological defence, but Australia did not participate in that research.

During the 1960s and 1970s, some research was conducted in an Australian Defence laboratory on toxins and venoms from Australian animals and plants. The research had no biological warfare focus, and was undertaken solely for the purpose of developing expertise in toxicology. The results of the research were published in scientific journals, contributing to the open scientific literature.

1970 to 1994

During this period, the policy was to maintain a watching brief on developments in biological warfare defence research so that a competency could be maintained to advise on policy and to give direction to training for the Australian Defence Force (ADF). This competency was derived from open literature and from Australia's partners under the TTCP. No research on defence against toxins (or other biological warfare agents) was undertaken during this period.

Australia did, however, maintain a research and development program into chemical defence, and the protective aspects of this program had some incidental common utility in biological defence.

1994 – Present

In 1994, it was recognised that Australia's knowledge of toxins as warfare agents needed to be strengthened if appropriate advice on defensive measures was to be given to the ADF and in support of the country's arms control objectives. Consequently, the Government gave approval to commence a modest program of research into defence against toxins as warfare agents.

It was also recognised that the Government needed advice on defence against biological weapons if it was to pursue its aims of strengthening the Biological Weapons Convention. Consequently, the policy of maintaining a watching brief on BW defence research was modified to allow research in BW defence that did not involve pathogenic reproducing organisms. This policy allowed research to include activities such as epidemiological studies, computer simulations and studies of the detection of toxins to be undertaken.

In 1998, government approval was given for DSTO to undertake biological defence work with reproducing organisms up to Risk Group 3. The subsequent program of work aims to mitigate the risk of use of biological weapons against Australian Defence personnel or civilians, and is in accordance with Australia's obligations under the BWC. Australia still maintains its active program into researching protective aspects of defence against chemical agents and has expanded the scope to include defence against biological weapons (e.g. incorporation of antibacterials in carbon absorbents).

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

CSL Limited is the primary manufacturer licensed by the Australian Government pursuant to the *Therapeutic Goods Act 1989* to manufacture vaccines for human use. The licence requires the manufacturer to comply with the principles of Good Manufacturing Practice.

1. Name of facility:

CSL Limited

2. Location (mailing address):

i) 45 Poplar Road Licence Number: MI-29112004-LI-000243-1
Parkville, Victoria 3052
Australia

ii) 189-209 Camp Road Licence Number: MI-06122004-LI-000279-1
Broadmeadows, Victoria 3047
Australia

3. General description of the types of diseases covered:

Vaccine products must be entered in the Australian Register of Therapeutic Goods (ARTG) prior to supply of the products for human use. The ARTG identifies the following vaccines as being manufactured by CSL Limited (not all of these vaccines were necessarily manufactured in 2013):

Influenza Vaccine
Q fever Vaccine
*Malarial Vaccine

* CSL Limited manufactures the Malarial Vaccine for another sponsor for export only.

Note: In regard to *Section 3, General Description of the Types of Diseases Covered*, CSL Limited sponsors a wide range of bacterial vaccines and viral vaccines that are manufactured overseas and imported into Australia for supply in Australia.

There are other manufacturers in Australia with a GMP licence issued by the TGA to produce biological goods – this category includes, but is not limited to, vaccines. The list of these facilities may be accessed from the TGA on-line services home page at www.tga.gov.au and by selecting the links to “Industry”, “Manufacturing therapeutic goods” followed by the Quick Link to “eBusiness Services” and then “Australian Manufacturers”.

A search of “Australian Manufacturers” identifies the following manufacturers licensed to manufacture vaccines for human use (additional to CSL Limited):

- Queensland Institute of Medical Research, 300 Herston Road, has been issued with a licence (MI-11112004-LI-000153-1) that authorizes the preparation and maintenance of cell banks only.
- Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg VIC, has been issued with a licence (MI-01072005-LI-000662-1) that authorises quality control testing, packaging and labelling, and release for supply of peptide vaccines, monoclonal antibodies, recombinant proteins & other clinical trial products.

Neither of these manufacturers are listed on the ARTG as sponsors of vaccines (i.e. responsible for the commercial supply).
